CNV, GWAS & Clinical Analysis Advancements in SVS

About this webinar

Recorded On: Wednesday, December 5, 2018

Copy number variation (CNV) can be drivers in many genetic diseases and can be called using our clinical and research application platforms: VarSeq and SVS, respectively. Using these platforms, CNV are called using the existing coverage data stored in your BAM files and are detected using a targeted or binned region approach. As the targeted approach has been demonstrated in previous webcasts, we wanted to focus on the binned region approach that is implemented for detecting CNV from shallow-coverage whole genome sequencing (WGS) data. In this webinar we will cover:

  • Providing an overview of how the binned region approach on whole genomes can be used to call large copy number events in both VarSeq and SVS
  • Additional analysis in SVS following the CNV calling steps that takes advantage of the rich research platform SVS provides
  • Other updates in the latest version of SVS to improve GWAS workflows
  • The addition of the Clinical Variant Scoring module to SVS to provide advanced variant annotations for functional predictions and conservation scores

SVS continues to be an industry-leading platform for genomic researchers studying humans as well as plant and animal species. Enjoy this webcast on whole-genome CNV calling and the latest capabilities of SVS!

Watch on demand

Please enjoy this webcast recording. Should you have any questions about the content covered, please reach out to our team here.

Download the slide deck

To download a copy of the slides, click on the LinkedIn icon. This will redirect you to the SlideShare site. From there, you can clip your favorite slides or download the entire deck to your computer.

Love this webcast? Check out more!

Find out how Golden Helix software enables users to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.